Metabolism of Ophthalmic Timolol: New Aspects of an Old Drug

Basic and Clinical Pharmacology and Toxicology

Volumn 108, Issue 5, 2011, Pages 297-303

  Volotinen, Marjo ^a   Hakkola, Jukka ^b   Pelkonen, Olavi ^b   Vapaatalo, Heikki ^a   Mäenpää, Jukka ^c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c Santen Oy   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIMATOPROST PLUS TIMOLOL; BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; CELECOXIB; CHOLINERGIC RECEPTOR STIMULATING AGENT; CIMETIDINE; CITALOPRAM; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 ISOENZYME; DORZOLAMIDE PLUS TIMOLOL; DRUG METABOLITE; ETORICOXIB; EYE DROPS; FLUCONAZOLE; FLUOXETINE; FLUVOXAMINE; LATANOPROST PLUS TIMOLOL; MIOTIC AGENT; PAROXETINE; PILOCARPINE; QUINIDINE; SERTRALINE; TERBINAFINE; TIMOLOL; TIMOLOL PLUS TRAVOPROST;

ALOPECIA; ANESTHESIA (SENSORY DYSFUNCTION); ANXIETY; AREA UNDER THE CURVE; BLEPHAROCONJUNCTIVITIS; BLURRED VISION; BRADYCARDIA; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONFUSION; CONJUNCTIVITIS; COUGHING; DEPRESSION; DIPLOPIA; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CHOICE; DRUG ERUPTION; DRUG FORMULATION; DRUG HYDROXYLATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRY EYE; DYSPNEA; FATIGUE; GLAUCOMA; HALLUCINATION; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYDROGEL; HYPOTENSION; INTRAOCULAR PRESSURE; LIVER METABOLISM; NASAL STUFFINESS; NOSE DISEASE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PTOSIS; PUNCTATE KERATITIS; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; SKIN DISEASE; SKIN IRRITATION; SYNCOPE; URTICARIA; VISUAL DISORDER; WEAKNESS;

ADMINISTRATION, TOPICAL; ADRENERGIC BETA-ANTAGONISTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2D6; EYE; GLAUCOMA; HEART RATE; HUMANS; INTRAOCULAR PRESSURE; LIVER; TIMOLOL;

EID: 79954538682     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2011.00694.x     Document Type: Review

References (47)

1. Brooks AMV, Gillies WE. Ocular β-blockers in glaucoma management. Clinical pharmacological aspects. Drugs Aging 1992;2:208-21.
2. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004;363:1711-20.
3. Lee DA, Higginbotham EJ. Glaucoma and its treatment: a review. Am J Health Syst Pharm 2005;62:691-9.
4. Nduaguba C, Lee R. Glaucoma screening: current trends, economic issues, technology, and challenges. Curr Opin Ophthalmol 2006;17:142-52.
5. Ekström C. Prevalence of open-angle glaucoma in central Sweden. The Tierp Glaucoma Survey. Acta Ophthalmol Scand 1996;74:107-12.
6. Brubaker R. Targeting outflow facility in glaucoma management. Surv Ohpthalmol 2003;48:S17-20.
7. Coca-Prados M, Escribano J. New perspectives in aqueous humor secretion and in glaucoma: the ciliary body as a multifunctional neuroendocrine gland. Prog Retin Eye Res 2007;26:239-62.
8. Johnson MC, Kamm RD. The role of Schlemm's canal in aqueous outflow from the human eye. Invest Ophthalmol Vis Sci 1983;24:320-5.
9. Kallaur K, Fingeret M Medical management of the glaucomas. In: Bartlett JD, Jaanus SD (eds). Clinical Ocular Pharmacology, 4th edn. Butterworth-Heinemann, Boston, MA, US, 2001; 831-85.
10. Fuchsjager-Mayrl G, Markovic O, Losert D, Lucas T, Wachek V, Muller M et al. Polymorphism of the β-2 adrenoceptor and IOP lowering potency of topical timolol in healthy subjects. Mol Vis 2005;11:811-5.
11. Schwartz K, Budenz D. Current management of glaucoma. Curr Opin Ophthalmol 2004;15:119-26.
12. Hoyng PF, van Beek LM. Pharmacological therapy for glaucoma: a review. Drugs 2000;59:411-34.
13. Neufeld AH, Bartels SP, Liu JHK. Laboratory and clinical studies on the mechanism of action of timolol. Surv Ophthalmol 1983;28:286-92.
14. Camras C, Hedman K. Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma. J Glaucoma 2003;12:466-9.
15. Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure. In the normal eye. Arch Ophthalmol 1978;96:2045-8.
16. Zimmerman TJ, Baumann JD, Hetherington J. Side effects of timolol. Surv Ophthalmol 1983;28:243-9.
17. Summary of product characteristics: Oftan Timolol 2.5mg/ml and 5mg/ml dated 7.9.2009.
18. Shell JW. Pharmacokinetics of topically applied ophthalmic drugs. Surv Ophthalmol 1982;26:207-18.
19. Nelson WL, Fraunfelder FT, Sills JM, Arrowsmith JB, Kuritsky JN. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985. Am J Ophthalmol 1986;102:606-11.
20. Nieminen T, Lehtimäki T, Mäenpää J, Ropo A, Uusitalo H, Kähönen M. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. Scand J Clin Lab Invest 2007;67:237-45.
21. Ghate D, Edelhauser H. Barriers to glaucoma drug delivery. J Glaucoma 2008;17:147-56.
22. Attar M, Shen J, Ling K-H, Tang-Liu D. Ophthalmic drug delivery considerations at the cellular level: drug metabolising enzymes and transporters. Expert Opin Drug Deliv 2005;2:891-908.
23. Sakanaka K, Kawazu K, Nishida K, Nakamura J, Nakashima M, Nakamura T et al. Transport of timolol and tilisolol in rabbit corneal epithelium. Biol Pharm Bull 2006;29:2143-7.
24. Volotinen M, Mäenpää J, Kautiainen H, Tolonen A, Uusitalo J, Ropo A et al. Ophthalmic timolol in a hydrogel vehicle leads to minor inter-individual variation in timolol concentration in aqueous humor. Eur J Pharm Sci 2009;36:292-6.
25. Edeki TI, He H, Wood AJJ. Pharmacogenetic explanation for excessive β-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction. JAMA 1995;274:1611-3.
26. Ishii Y, Nakamura K, Tsutsumi K, Kotegawa T, Nakano S, Nakatsuka K. Drug interaction between cimetidine and timolol ophthalmic solution: effect on heart rate and intraocular pressure in healthy Japanese volunteers. J Clin Pharmacol 2000;40:193-9.
27. Dinai Y, Sharir M, Naveh N, Halkin H. Bradycardia induced by interaction between quinidine and ophthalmic timolol. Ann Intern Med 1985;103:890-1.
28. Sikka R, Magauran B, Ulrich A, Shannon M. Bench to bedside: pharmacogenomics, adverse drug interactions, and the cytochrome P450 system. Acad Emerg Med 2005;12:1227-35.
29. Ingelman-Sundberg M, Rodriguez-Antona C. Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Phil Trans R Soc B 2005;360:1563-70.
30. Pelkonen O, Mäenpää J, Taavitsainen P, Rautio A, Raunio H. Inhibition and induction of human P450 (CYP) enzymes. Xenobiotica 1998;28:1203-53.
31. Nieminen T, Uusitalo H, Turjanmaa V, Bjärnhall G, Hedenström H, Mäenpää J et al. Association between low plasma levels of ophthalmic timolol and haemodynamics in glaucoma patients. Eur J Clin Pharmacol 2005;61:369-74.
32. Yuan H, Yu M, Yang Y, Wu K, Lin X, Li J. Association of CYP2D6 single-nucleotide polymorphism with response to ophthalmic timolol in primary open-angle glaucoma - a pilot study. J Ocul Pharmacol Ther 2010;26:497-501.
33. Yang Y, Wu K, Yuan H, Yu M. Cytochrome oxidase 2D6 gene polymorphism in primary open-angle glaucoma with various effects to ophthalmic timolol. J Ocul Pharmacol Ther 2009;25:163-71.
34. Volotinen M, Turpeinen M, Tolonen A, Uusitalo J, Mäenpää J, Pelkonen O. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. Drug Metab Dispos 2007;35:1135-41.
35. Volotinen M, Korjamo T, Tolonen A, Turpeinen M, Pelkonen O, Hakkola J et al. Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryopreserved hepatocytes. Basic Clin Pharmacol Toxicol 2010;106:302-9.
36. Offord E, Shafir A, Macé K, Tromvoukis Y, Spillare E, Avanti O et al. Immortalized human corneal epithelial cells for ocular toxicity and inflammation studies. Invest Ophthalmol Vis Sci 1999;40:1091-101.
37. Doshi M, Marcus C, Bejjani B, Edward D. Immunolocalization of CYP1B1 in normal, human, fetal and adult eyes. Exp Eye Res 2006;82:24-32.
38. Vasiliou V, Gonzalez FJ. Role of CYP1B1 in glaucoma. Annu Rev Pharmacol Toxicol 2008;48:333-58.
39. Zhang T, Xiang CD, Gale D, Carreiro S, Wu E, Zhang E. Drug transporter and CYP P450 mRNA expression in human ocular barriers: implications for ocular drug disposition. Drug Metab Dispos 2008;36:1300-7.
40. Volotinen M, Mäenpää J, Kankuri E, Oksala O, Pelkonen O, Nakajima M et al. Expression of cytochrome P450 (CYP) enzymes in human non-pigmented ciliary epithelial cells; induction of CYP1B1 expression by TCDD. Invest Ophthalmol Vis Sci 2009;50:3099-105.
41. WuDunn D. Genetic basis of glaucoma. Curr Opin Ophthalmol 2002;13:55-60.
42. Lopez-Garrido M-A, Sanchez-Sanchez F, Lopez-Martinez F, Aroca-Aguilar J-D, Blanco-Marchite C, Coca-Prados M et al. Heterozygous CYP1B1 gene mutations in Spanish patients with primary open-angle glaucoma. Mol Vis 2006;12:748-55.
43. Volotinen M. Expression of Cytochrome P450-Enzymes and Metabolism of Timolol in Human Ocular Tissue. Helsinki University, Helsinki 2009; 70.
44. Mäntylä R, Männistö P, Nykänen S, Koponen A, Lamminsivu U. Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. Eur J Clin Pharmacol 1983;24:227-30.
45. Dollery C, Boobis AR, Burley D, Davies DS, Harrison PI, Orme ML et al. Timolol (maleate), In Dollery C (ed.). Therapeutic Drugs. vol 2. Churchill Livingstone, Edinburgh, 1991; T77-80.
46. Sarfarazi M. Recent advances in molecular genetics of glaucomas. Hum Mol Genet 1997;6:1667-77.
47. Stoilov I, Akarsu AN, Alozie I, Child A, Barsoum-Homsy M, Turacli ME et al. Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am J Hum Genet 1998;62:573-84.